

# Clinical trials of intensive blood pressure control for hypertension in non diabetic patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 Treatment blood pressure target

| Trial   | Treatments   | Patients  | Trials design and methods              |
|---|--|---|--|
| <b>more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie</b> |  |   |  |
| SPRINT , 2015<br>[NCT01206062]<br>n=4678/4683<br>follow-up:   | target of 120 mm Hg<br>versus<br>target of 140 mm Hg   | high-risk hypertensive adults 50 years of age and older with one additional cardiovascular risk factor or preexisting kidney disease  | Parallel groups<br>open                |
| Cardio-Sis , 2009<br>[NCT00421863]<br>n=558/553<br>follow-up: 2 years                                       | tighter control of systolic BP with a goal of <130 mm Hg<br>versus<br>usual control, with a goal of <140 mm Hg                               | nondiabetic patients with hypertension and with SBP of 150 mm Hg or higher confirmed at two different times   | Parallel groups<br>open<br>Italy       |
| HOT , 1994<br>n=12526/6264<br>follow-up: 3.8 y  | less or equal than 85 mmHg, or less or equal than 80 mmHg<br>versus<br>less or equal than 90 mmHg  | patients with diastolic blood pressure between 100 mmHg and 115 mmHg  | Factorial plan<br>open<br>26 countries |
| REIN-2 , 2005<br>n=169/169<br>follow-up: 36 months  | intensified (systolic/diastolic <130/80 mm Hg) blood-pressure control<br>versus<br>conventional (diastolic <90 mm Hg) blood-pressure control | patients with non-diabetic proteinuric nephropathies receiving background treatment with the ACE inhibitor ramipril   | open                                   |
| MDRD , 1994<br>n=840<br>follow-up: 2.2 y  | low target blood pressure (mean arterial pressure <92 mm Hg)<br>versus<br>usual target blood pressure (mean arterial pressure <107 mm Hg)    | patients with predominantly nondiabetic kidney disease and a glomerular filtration rate of 13 to 55 mL/min per 1.73 m <sup>2</sup>  | open                                   |
| Toto , 1995<br>n=42/35<br>follow-up:  | strict blood pressure control (DBP 65 to 80 mm Hg)<br>versus<br>usual blood pressure control (DBP 85 to 95 mm Hg)                            | non-diabetic patients (age 25 to 73) with long-standing hypertension (DBP >or = 95 mm Hg), chronic renal insufficiency (GFR <or = 70 mL/min/1.73 m <sup>2</sup> ) and a normal urine sediment | open                                   |

## References

### SPRINT, 2015:

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015 Nov 9;: [26551272] 10.1056/NEJMoa1511939

### Cardio-Sis, 2009:

Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525-33 [19683638]

#### **HOT, 1994:**

Hansson L, Zanchetti A, Carruthers SG, Dahlf B, Elmfeldt D, Julius S, Mnard J, Rahn KH, Wedel H, Westerling S Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62 [9635947]

Hansson L, Zanchetti A The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Press 1997;6:313-7 [9360003]

Hansson L, Zanchetti A The Hypertension Optimal Treatment (HOT) Study—patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press 1994;3:322-7 [7866597]

Zanchetti A, Hansson L, Dahlf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel H Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001;19:1149-59 [11403365]

#### **REIN-2, 2005:**

Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonards D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939-46 [15766995] 10.1016/S0140-6736(05)71082-5

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13 [9732337]

#### **MDRD, 1994:**

Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84 [8114857]

Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997;29:641-50 [9040451]

Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62 [7574193]

Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005;142:342-51 [15738453]

#### **Toto, 1995:**

Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995;48:851-9 [7474675]

## **2 About TrialResults-center.org**

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.